In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi is joined by Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health. Dr. Rajagopalan explains why Fractyl shifted its focus from treating type 2 diabetes to helping former GLP-1 users maintain their weight loss with Revita, an outpatient endoscopic procedure designed to target the root causes of metabolic disease in the duodenum. He also shares new clinical data, the strategy behind Fractyl&#x27;s pivotal trial, the company&#x27;s commercialization plans, and why he believes metabolic endoscopy could become an entirely new category of care. This episode is brought to you by the DeviceTalks Interventional Innovations series, July 28-30th. To register for this complimentary series, click here. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:01:35) - Keynote Interview - Harith Rajagopalan, MD, PhD, Co-Founder and Chief Executive Officer, Fractyl Health (00:06:26) - Starting with Back of the Napkin Idea (00:18:45) - Why patients are enthusiastic (00:24:35) - The Parallels to Renal Denervation (00:29:40) - Commercial Plans, Pivotal Trials &amp; What&#x27;s Next


                    Is Fractyl poised to create a new MedTech market by helping former GLP-1 users keep weight off?
                

DeviceTalks Podcast Network

Are you ready for this? Ready This is Tom Salemi of DeviceTalks, welcome back to the DeviceTalks Weekly Podcast We have, they call it in the West Wing, they call it a bottle episode

I think one of those episodes you can just sort of tick off the shelf and plug it in This is one of those, I'm at SRS this week, so don't have time to do the newsmakers or the FOMOs But did want to share this great conversation I had with Harith Rajagopalian He's the CEO of Fractyl Health Fractyl Health has been an amazing company to follow And they're moving into a potentially enormous space, the GLP-1 space

And helping people to maintain the weight loss that they've achieved using GLP-1s without remaining on GLP-1s So huge opportunity for Fractyl Health, huge opportunity for other MedTech companies as well We'll explore Fractyl Health's history, its recent redirection, and its future in this conversation So once again, enjoy this single conversation No newsmakers, no FOMO, just me and Harith Rajagopalian and my inability to say duodenum

I don't know why I couldn't say it, but next time I'll practice So thanks everyone for tuning in, let's get this podcast started Well Harith Rajagopalian, welcome back to the podcast Thank you Tom, so great to see you again Great to have you back, it's one of the stories I've enjoyed following through the years And we don't need to go way back, you've been on the podcast a few times talking about your move into MedTech

But I think folks would love sort of a brief overview of Fractyl Health You've been around for, is it 16 years? Founded in 2020? 15 years 15 years Give us a brief sense of how it was started And then...

Is Fractyl poised to create a new MedTech market by helping former GLP-1 users keep weight off?

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Is Fractyl poised to create a new MedTech market by helping former GLP-1 users keep weight off?

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.